September 09, 2020

Chinese Biotech Sector is Blowing Hot as M&A and IPO Deals Surge Amid Covid-19 Pandemic

Toto Ku, Datasite Senior Sales Director, provides comments on the outlook for the Chinese biotech sector, including the surge in M&A and IPO deals amid the COVID-19 pandemic. The South Morning China Post article highlights findings from a recent webinar discussion on Deal Drivers in the Healthcare and Life Sciences: Mainland China.

  • Datasite for Healthcare

    Navigating the healthcare and life sciences industry has never been harder. Whether you’re looking at a licensing, listing or M&A, achieve your objective quickly and keep sensitive data secure with Datasite.

Contacts

Media Relations
Marta Carraro

Vice President, Communications

212.367.6162

[email protected]

Investor Relations
Jennifer Percy

Senior Vice President, Finance & Treasury

651.632.4009

[email protected]

You may also like:

After 2022's Turmoil, What's Next For the City and M&A?

EMEA CRO Merlin Piscitelli writes about the outlook for M&A in 2023, the importance of being deal ready, and getting the fundamentals of deal execution right to capture maximum value.

Benzinga
Smartphones are the new Laptops With 60 Percent of UK Firms now Mobile Only – BT

EMEA CRO Merlin Piscitelli discusses why the TMT sector may experience more consolidation this year.

City AM logo
After a Challenging Year for Dealmaking, What’s the 2023 UK M&A Outlook?

EMEA CRO Merlin Piscitelli writes about what’s on the horizon for UK M&A and other capital transactions in 2023.